DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...

Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from ...

DexCom (DXCM) stock declines after a short report, yet analysts from TD Cowen and Baird stay bullish on the company's ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...

The report claims that inaccurate readings from the G7 device have resulted in hospitalizations and deaths among diabetic patients. According to Hunterbrook, an FDA inspection revealed DexCom made an ...

Investing.com - Oppenheimer downgraded DexCom (NASDAQ:DXCM) stock rating from Outperform to Perform on Monday, citing multiple challenges facing the continuous glucose monitoring device maker.

As the effects of climate change and ecological decline intensify, the need for accurate, scalable environmental monitoring has never been more urgent. From tracking urban air quality to safeguarding ...

From better sleep to less stress, doctors share their thoughts on how different technology can help support our well-being.

BTIG analysts said Senseonics is doubling down on its belief an inflection point in patient demand is imminent, but the company will need a large sales force to win market share.

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the ...